. These actions reflect the involvement of specific miRNAs in fundamental cellular processes, such as cell survival (miR-15) 13 , extracellular matrix production (miR-21 and miR-29) 9 ,10 and hypoxia (miR-210) 14 . The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors or mimics, and the recent success of the first-in-human clinical trial of a miRNA therapeutic for suppression of hepatitis C virus (HCV) replication
, have both raised possibilities for a new class of disease-modifying therapeutics based on miRNA biology. miRNA-based therapeutics have not yet reached clinical trials for cardiovascular disorders, but the promising results in numerous animal models of related diseases such as heart failure, cardiac hypertrophy, fibrosis and hyperlipidaemias, as discussed below, suggest that clinical data will soon be available.
Here, we review the mechanistic basis of miRNA functions within the context of disease modification and consider the roles of representative miRNAs in cardiovascular disease. With this perspective, we evaluate miRNAs as potential therapeutic targets for cardiovascular disorders and consider the challenges associated with this potential new therapeutic modality.
miRNA biogenesis and mechanism of action Mature miRNAs are ~22 nucleotides in length and are transcribed by RNA polymerase II as long precursor RNAs, called primary miRNAs (pri-miRNAs), which are sequentially processed in the nucleus and cytoplasm. The RNase III Drosha associates with DiGeorge syndrome critical region 8 (DGCR8) and other cofactors RNA-induced silencing complex (RISC) . A multiprotein complex that incorporates a microRNA to recognize complementary sequences in mRNAs and block protein expression.
Pseudogenes
Non-coding transcripts that are often conserved across species and contain conserved microRNA binding sites that can act as decoys to interfere with microRNA activity.
AntimiRs
Antisense oligonucleotides designed to target specific microRNAs.
to crop pri-miRNAs in the nucleus, yielding hairpinshaped pre-miRNAs (~70 nucleotides in length) that are further shortened in the cytoplasm by Dicer to give rise to the mature miRNA 15 . In the cytoplasm, miRNAs associate with mRNAs within a multiprotein complex of Argonaute proteins, known as the RNA-induced silencing complex (RISC), which facilitates and stabilizes miRNAmRNA interactions. miRNAs anneal via Watson-Crick base pairing, with sequences most commonly located in 3ʹ untranslated regions (UTRs) of mRNA 15 , although there are some examples of miRNA interactions within mRNA coding regions, intron-exon junctions and 5ʹ UTRs 16, 17 . The primary determinant of mRNA target regulation by miRNAs is perfect pairing between the sequence of nucleotides 2-7 at the 5ʹ end of the mature miRNA (referred to as the 'seed region') and the target mRNA, but other nucleotides also contribute to the interactions 15 . Association of a miRNA with its mRNA target results in degradation of the mRNA as well as inhibition of translation (FIG. 1) . Currently, it is believed that the vast majority of the gene-regulatory effects of miRNAs occur though mRNA decay rather than translational repression 18 . Recently, pseudogenes have also been implicated in regulating miRNA activity. Pseudogene transcripts containing conserved miRNA binding sites, referred to as competing endogenous RNAs (ceRNAs), act as decoys or sponges by sequestering miRNAs and preventing them from binding to their mRNA targets 19, 20 . An especially puzzling feature of miRNA biology has been the minimal effects of miRNA-mediated loss of function. Although lin-4, the first miRNA to be discovered, was identified on the basis of its strong loss-offunction phenotype in nematodes, systematic genetic deletions of miRNAs in this organism have revealed grossly abnormal phenotypes in less than 10% of miRNAmutant animals 21 . Similarly, genetic analyses of miRNAs in mice have revealed relatively minor functions under conditions of homeostasis in controlled laboratory settings 22 . The lack of strong loss-of-function miRNA phenotypes might be explained by compensatory mechanisms that allow for re-balancing of protein networks when the expression of individual components is subtly altered as a consequence of the absence of a miRNA.
Redundancy among homologous miRNAs within families or the targeting of individual mRNAs by several miRNAs can also diminish the consequences of the loss of individual miRNAs. However, a general theme seems to be that the actions of miRNAs become pronounced under conditions of injury or stress. Thus, the elimination of some miRNAs sensitizes cells to stress, resulting in exacerbated pathology, whereas the absence of other miRNAs can confer resistance to stress. Stress signalling impinges on numerous points in the pathway of miRNA biogenesis and function (FIG. 1) . There are many examples in which miRNA abundance increases or decreases in response to stress, and changes in the expression of specific miRNAs have been shown to be diagnostic for disease progression in cardiovascular disorders 23 . The heightened function of a miRNA during stress can also be explained by changes in the abundance of its mRNA targets or differences in miRNA activity under stress 24 . For example, a stress-induced reduction in the level of expression of a miRNA can have a disease-modifying effect by increasing the levels of downstream mRNA targets, whereas a stress-induced increase in miRNA expression will result in a decrease in levels of downstream targets. Conversely, changes in the expression of mRNA targets under disease conditions can influence the effect of the miRNA on the mRNA. Although the influence of stress is likely to be miRNA-and trigger-dependent, changes in miRNA expression and functionality under disease conditions imply the existence of an active mechanism for differential miRNA activity under stress.
Therapeutic inhibition of miRNAs
Genetic gain-and loss-of-function approaches, as well as pharmacological modulation of individual miRNAs or miRNA families in animal models of disease, point to miRNAs as key regulators of many disorders, including cardiovascular disease 23 . Their pathological roles, along with their pharmacological properties, have catalysed efforts to develop miRNA therapeutics. In principle, miRNA mimics can be used to elevate the expression of beneficial miRNAs in disease settings, whereas miRNA inhibitors can be delivered to block the activity of miRNAs that drive disease progression 25 . miRNA mimicry has lagged behind the development of antimiR chemistries owing to substantial challenges in their delivery and design. Currently, the most effective means of enhancing miRNA function or replacing miRNAs that are lost or downregulated in disease is through adeno-associated viruses (AAVs). The availability of numerous different AAV serotypes allows for potential tissue enrichment as a result of the natural tropism of each individual AAV Box 1 | Clinical trials of antimiR-122 in the treatment of HCV AntimiR therapeutics (inhibitors of microRNAs) recently became a reality when Santaris Pharma reported both the safety and efficacy of its antimiR against the microRNA miR-122, miravirsen, in humans. Data from a Phase I trial showed that either a single dose (up to 12 mg per kg) or multiple ascending doses (up to five doses of 5 mg per kg) of miravirsen are well tolerated in healthy volunteers. These studies indicated that miravirsen has an attractive pharmacokinetic profile and a clear dose-dependent pharmacology, without having dose-limiting toxicities at the doses used in these studies.
A follow-up Phase IIa trial (see the 3 October 2011 press release on the Santaris Pharma website) indicated that miravirsen was well tolerated and provided continuous and prolonged antiviral activity that extended well beyond the end of active therapy in patients infected with hepatitis C virus (HCV). In this multipleascending-dose study, patients were enrolled sequentially to one of three cohorts (nine active: three placebo per cohort) and miravirsen was administered at doses of 3, 5 or 7 mg per kg with a total of five weekly subcutaneous injections over 29 days. Treatment with miravirsen provided robust, dose-dependent antiviral activity that was maintained for more than 4 weeks after the last dose. Notably, in four out of nine patients treated at the highest dose (7 mg per kg), HCV RNA became undetectable during the study. No serious adverse events were observed and only mild and infrequent adverse events such as headaches, coryza and diarrhoea were reported. Furthermore, there were no clinically significant changes in safety tests, vital signs or electrocardiograms. Taken together, these data indicate that miravirsen, given as a 4-week monotherapy to patients with HCV, provides long-lasting suppression of viraemia and provides a strong barrier to viral infection.
Additional Phase II studies of miravirsen are planned in combination with direct-acting antivirals and as a single agent. 
Pharmacodynamic
In the context of antimiR (microRNA inhibitor) designs, this refers to mRNA de-repression of direct microRNA targets in response to treatment with an antimiR.
serotype towards different organs, as well as the different cellular receptors with which each AAV serotype interacts 26, 27 . AAV type 6 and type 9, for example, display preferential tropism for skeletal muscle and heart, respectively, when delivered systemically in rodents [28] [29] [30] . Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs.
AntimiR chemistries. miRNAs possess several features as potential drug targets that distinguish them from other therapeutic modalities. In contrast to small-molecule inhibitors identified in cell-based screens, in which target identification can pose substantial challenges, antimiRs act through complementary base pairing with miRNAs, so their direct target sequence in mRNAs is known -at Figure 1 | MicroRNA biogenesis and mechanism of action. MicroRNA (miRNA) genes are usually transcribed by RNA polymerase II (Pol II) to form a capped and polyadenylated transcript. The miRNA precursor, termed primary miRNA (pri-miRNA), forms a hairpin-shaped loop structure that is cleaved by the RNase III Drosha and DiGeorge syndrome critical region 8 (DGCR8), yielding a hairpin-shaped precursor miRNA (pre-miRNA) that is ~70 nucleotides in length. The pre-miRNA is exported from the nucleus into the cytoplasm, where it is further cleaved by the RNase III enzyme Dicer, yielding an imperfect miRNA-miRNA* duplex that is about 22 nucleotides in length. Although either strand of the duplex may potentially act as a functional miRNA, only one strand is usually incorporated into the RNA-induced silencing complex (RISC). miRNAs incorporated in the RISC often recognize their targets -nucleotides 2-7 of miRNA (known as the 'seed region'). Association of a miRNA with its mRNA target results in degradation of the mRNA as well as translational inhibition. Recently, pseudogenes have also been implicated in regulating miRNA activity. Pseudogene transcripts are often conserved across species and many contain conserved miRNA binding sites, referred to as competing endogenous RNAs (ceRNAs), which act as decoys or sponges by sequestering miRNAs and preventing them from binding to their mRNA targets. Stress conditions can influence miRNA biogenesis at multiple levels (indicated on the figure by lightening bolts). lncRNA, long non-coding RNA; m least theoretically. However, it should also be emphasized that there is substantial ambiguity in miRNA target identification, in that sequences outside the miRNA 'seed region' -as well as the secondary structure of the mRNA target and the association of mRNAs with RNA-binding proteins -can influence target engagement 31 . Thus, it is essential to experimentally document the regulation of specific targets in response to changes in miRNA abundance in order to firmly establish their contributions to miRNA functions.
Several oligonucleotide chemistries allow for highaffinity interaction of antisense oligonucleotides with miRNAs, preventing their interaction with -and repression of -target mRNAs. To achieve effective pharmacological inhibition of disease-associated miRNAs, antimiR chemistries should contain chemical modifications to enhance binding affinity, confer nuclease resistance and facilitate cellular uptake. To increase nuclease resistance, most antimiR chemistries to date harbour phosphorothioate backbone linkages (FIG. 2) . In addition to increasing stability, the phosphorothioate backbone modifications promote plasma protein binding, thereby reducing clearance of the antimiRs by glomerular filtration and urinary excretion, which facilitates tissue delivery of antimiRs in vivo [32] [33] [34] . AntimiRs containing cholesterol, conjugated via a 2ʹ-O-methyl (2ʹ-O-Me) linkage, named antagomirs, are fully complementary to the mature miRNA sequence and contain several phosphorothioate moieties to increase stability (FIG. 2) . Cholesterol is thought to enhance cellular uptake and in vivo stability 32, 33 , as well as promote hepatic uptake of the antimiR while lowering delivery to other tissue types.
The antagomir chemistry has been especially useful as an experimental tool; however, all antimiR chemistries currently in development use unconjugated phosphorothioate antisense molecules with various additional highaffinity 2ʹ sugar modifications such as 2ʹ-O-methoxyethyl (2ʹ-MOE) and 2ʹ-fluoro (2ʹ-F) or locked nucleic acid (LNA) and LNA-like conformationally restricted nucleotides (FIG. 2) . Although all of these modifications improve nuclease resistance and increase duplex melting temperature (T m ) 35 , LNAs possess the highest affinity, with an increase To increase nuclease resistance, most antimiR chemistries to date harbour phosphorothioate backbone linkages, whereby a sulphur atom replaces one of the non-bridging oxygen atoms in the phosphate group. AntimiRs containing cholesterol, conjugated via a 2ʹ-O-Me linkage, named antagomirs, are fully complementary to the mature miRNA sequence and contain several phosphorothioate moieties to increase their stability. Several unconjugated phosphorothioate antisense molecules with various high-affinity 2ʹ sugar modifications (such as 2ʹ-MOE, 2ʹ-F or LNA) are currently also being used. Although all of these modifications improve nuclease resistance and increase duplex melting temperature, the high duplex melting temperature of LNA-modified oligonucleotides enables efficient miRNA inhibition with shorter antimiRs. 
P-bodies
Cytoplasmic sites of mRNA turnover. Also referred to as stress granules.
in T m of +2 °C to +8 °C per introduced LNA modification against complementary RNA. A 2ʹ-MOE-modified antimiR-122 has shown efficacy in mice 36 , and an LNAmodified antimiR-122 has been shown to be efficacious in non-human primates 37 . Moreover, LNA-modified antimiR-122 was recently shown to be efficacious in humans (see the ClinicalTrials.gov website). A 2ʹ-F-and 2ʹ-MOE-modified antimiR-33 was recently shown to be efficacious in reducing atherosclerosis in non-human primates 38 . The high T m of LNA-modified oligonucleotides enables efficient miRNA inhibition with truncated antimiRs. Several studies have reported efficient miRNA inhibition in vivo, using high-affinity 15-16-nucleotide-long LNA-DNA mixmers targeting the 5ʹ region of mature miRNA. The high binding affinity of seed region-targeting tiny 8-mer LNA-modified antimiRs with a complete phosphorothioate backbone allows for in vivo delivery and silences miRNAs without the need for additional conjugation or formulation chemistries 13, [39] [40] [41] (FIG. 2) . Microarray analysis indicated that 8-mers and 15-mers evoked comparable changes in miR-122 targets in the liver and induced similar physiological responses 39 . However, as many miRNAs belong to families that differ by only a few bases in the 3ʹ regions, antimiRs that are complementary to the fulllength miRNA sequence may have greater specificity towards individual miRNA family members than shorter antimiRs that are directed against 5ʹ regions of miRNAs.
Potential sources of toxicity after the administration of a miRNA inhibitor include unwanted gene changes or the effects of the antimiR on off-target, non-diseased tissues; the chemistry of the antimiR is also a common source of toxicity for oligonucleotide therapeutics. Phosphorothioate oligonucleotides, for example, can inhibit the tenase complex in the intrinsic clotting cascade 42 , activate the alternative pathway of the complement cascade 43 and activate innate immunity. Additionally, although LNA-containing oligonucleotides have an increased potency for reducing the levels of mRNA targets, some signs of hepatotoxicity (determined by measuring serum levels of transaminases, liver weight and body weight) have been observed with LNA-modified antisense oligonucleotides directed against mRNAs. Histopathological evaluation of tissues from LNA-treated animals confirmed the hepatocellular involvement, suggesting that although LNA-modified antisense oligonucleotides have the potential to improve potency, they potentially create a risk of developing hepatotoxicity 44 . However, contrary to this report, no hepatotoxicity was observed in mice treated with LNA-modified antimiRs (at a dose of 75 mg per kg; three doses of 25 mg per kg per day), as shown by unaltered levels of the serum transaminases alanine aminotransferase and aspartate aminotransferase 24 hours after treatment (compared to saline controls) and by the absence of histological changes in liver sections from LNA-treated animals 45 . Further toxicity studies of chemically modified miRNA inhibitors will be required to establish safety parameters for the different antimiR chemistries. Different oligonucleotide sequences are also likely to display differences in toxicity, tissue distribution and efficacy.
Pharmacokinetic properties of antimiR chemistries. The antimiR molecules that are currently being used to target miRNAs in vivo are highly water-soluble and have molecular masses of several kDa. Their size and charge limit intestinal absorption, thereby preventing them from becoming good candidates for oral administration. Thus far, successful delivery of chemically modified oligonucleotide antimiRs has been dependent on parenteral administration via intravenous (i.v.), intraperitoneal (i.p.) or subcutaneous (s.c.) injection. Unlike typical (low-molecular-mass) drugs, plasma levels of antimiR chemistries are largely cleared within hours after administration as a result of their uptake into tissues 34, 46 , except for a low level of antimiR that remains detectable in the circulation for several weeks 13, 39 . The persistent presence of the antimiR in the circulation probably reflects its association with circulating plasma proteins and/or the gradual release of antimiRs trapped in extracellular spaces.
Studies using northern blotting, enzyme-linked immunosorbent assay (ELISA)-based detection methods or fluorescently labelled oligonucleotides have shown that antimiRs containing the typical nucleic acid ribose sugar backbone with 2ʹ modifications are distributed broadly to most tissues but tend to accumulate in the kidney and liver 13, 32, 33, 45, 47 . However, it is becoming apparent that oligonucleotide sequence, length and chemical modifications affect cellular distribution and functionality, thus strongly influencing the pharmacokinetic and pharmacodynamic properties of each molecule 32, 33, 36, 39 . Currently, relatively little is known about the mechanisms of cellular uptake, storage and mode of action of the different antimiR chemistries. Once inside cells, many modified antimiRs are extremely stable and have half-lives in the order of weeks 48 . Additionally, although systemically delivered antagomirs appear to accumulate in a cytoplasmic compartment distinct from P-bodies and induce miRNA degradation by an RNA interference (RNAi)-independent pathway 32, 33 , LNA-modified antimiRs seem to inhibit miRNA function by sequestering the mature miRNA 45, 47 , which implies that the different antimiR chemistries have different modes of action.
In the context of this Review, although it is clear that oligonucleotide chemistries directed against miRNAs are taken up by, or at least reach, cardiac and vascular cell populations, it will be interesting to determine whether some cell types are more efficiently targeted and whether stress plays a part in cellular uptake. Another question that remains unanswered is where within the cell the antimiRs reside and whether all antimiRs are actually functional. Currently used doses provide a vast excess of antimiR copies relative to miRNA, and the long-lasting duration of effects suggests that there is a cellular reservoir that -over time -enables antimiRs to inhibit newly formed miRNAs, but it is unknown how the release of antimiRs from such cellular depots is controlled. Subcellular sites of antimiR storage, as well as the kinetics of release, may vary depending on the chemical modifications to the oligonucleotide.
MyomiRs
The collection of microRNAs co-expressed with three different myosin heavy chain (MYH) genes: MYH6 (miR-208a), MYH7 (miR-208b) and MYH7B (miR-499).
Efficacy of antimiRs.
Although antimiR detection studies indicate that there is a rapid uptake of antimiR chemistries in many tissues, unless the antimiR is located within the appropriate cellular compartment, these assays can be deceptive as the in vivo activity of an antimiR is determined by its cellular distribution. Processing of tissue during experimental analysis can potentially introduce artificial binding between the antimiR and miRNA, which does not actually occur within the intact cell, leading to an overestimation of antimiR function and binding.
The impact of a miRNA on its target depends on the relative ratio of a miRNA to its target. miRNAs display a range of intracellular concentrations, with the most abundant miRNAs being expressed at up to tens of thousands of copies per cell 49 . Strategies to inhibit miRNA function and thereby de-repress expression of their targets are based on the presumption that relatively modest increases in the expression of targets are sufficient to evoke substantial therapeutic benefits. In this regard, the mRNA targets of miRNAs have been shown to display threshold effects such that the mRNA can be efficiently repressed when it is present at relatively low levels compared to the miRNA, but when the mRNA reaches such a level that the miRNA is not able to inhibit it, the biological impact of the miRNA becomes diminished 50 . In order to demonstrate the efficacy of target engagement by antimiRs in vivo, it is necessary to measure target de-repression. This task is burdened by the fact that target regulation in general is modest, rangingon average -from a 20% to 50% change in mRNA expression, making it difficult to determine significant changes above naturally occurring variations in gene expression 18, 51 . Additionally, proteomic studies in response to miRNA modulation have reported that the average changes in protein levels of miRNA targets are less than twofold following miRNA inhibition 52, 53 . Target de-repression is often dependent on stress conditions, whereby both the severity and the type of cellular stress influence whether an mRNA is regulated by a miRNA. This is probably due to an abundance of mRNA targets and the expression of cofactors regulating the activity of miRNAs (FIG. 1) .
The time course and nature of the pharmacological effects (or pharmacodynamics) of antimiRs are often complicated by the fact that the pharmacology is the summation of the de-repression of gene families and downstream events caused by the de-repression of multiple target genes controlled by that particular miRNA. Thus, the onset of the functional efficacy of antimiRs can be delayed by days or weeks following initial administration of the drug, as reported for the miR-122 inhibitor and its effects on serum cholesterol levels 9 . Delays in pharmacodynamic effects are atypical for most lowmolecular-mass drugs and are more akin to so-called disease-modifying agents wherein it is established that pharmacological activity is related to the sum of pharmacological effects over time that cause a change in the disease phenotype. The delayed actions of at least some antimiRs suggest that this class of potential drugs may be better suited for chronic rather than acute disease indications. It should be noted that in these same studies it was shown that the downstream effect of antimiR treatment appeared to be reversible 45, 47 . miRNA targets in cardiovascular disease Although a long-standing dogma in the small interfering RNA (siRNA) field has been that the heart is resistant to oligonucleotide uptake, it has been well established that the heart effectively takes up exogenous DNA 54 . Indeed, several studies have demonstrated effective cardiac delivery and miRNA inhibition using antimiR chemistries and have indicated the potent effects of miRNA inhibition under disease conditions. Below, we present some recent representative examples of the therapeutic effects of antimiRs in the cardiovascular system (TABLE 1) .
Control of pathological cardiac remodelling and obesity by miR-208. Myosin heavy chain protein (encoded by MYH genes) is the major contractile protein of striated muscles, and myosin 6 (encoded by MYH6; also known as MyHC-α) is the predominant myosin isoform expressed in the adult rodent heart. An intron of this gene encodes miR-208a, which -like the host gene -is expressed specifically in the heart 55, 56 . Two related miRNAs, miR-208b and miR-499, are encoded by introns of the MYH7 (encoding myosin 7; also known as MyHC-β) and MYH7B genes, respectively, which are expressed specifically in cardiac and slow skeletal muscle 57 . Knockout mice lacking each of these miRNAs (referred to as myomiRs) are viable, but miR-208b-miR-499 doubleknockout mice display a reduction in slow myofibres and a corresponding increase in fast myofibres, which is consistent with a role for these miRNAs in the regulation of myofibre switching 57 . Most relevant to cardiac disease is the finding that miR-208a-knockout mice display reduced fibrosis and hypertrophy in response to cardiac stress, and fail to upregulate myosin 7 expression, which is a sensitive marker of pathological cardiac remodelling 56 . These findings initially suggested that therapeutic inhibition of miR-208a might evoke similar benefits in settings of heart disease. Indeed, Montgomery et al. 48 showed that subcutaneous delivery of an LNA-modified oligonucleotide inhibitor directed against miR-208a induced potent and functional inhibition of the cardiomyocyte-specific miR-208a. Inhibition of miR-208a suppresses fibrosis, diminishes myosin 7 expression and improves survival in Dahl salt-sensitive rats, which are susceptible to diastolic dysfunction when maintained on a high-salt diet 48 . These findings provide proof-of-concept support for the potential therapeutic benefit of antimiR-208a agents in the setting of heart disease. This study also showed that the antimiR was detectable in the heart for up to 6 weeks following i.v., s.c. or i.p. delivery (whereas higher levels of the antimiR were detected in the kidney and liver) and that a low level of the antimiR remained detectable in the plasma for a comparable period 48 . Interestingly, the downregulation of myosin 7 expression in the heart in response to antimiR-208a was delayed 48 , which mirrors the delay in cholesterol lowering after miR-122 inhibition. Whether oligonucleotide inhibition of miR-208a
MED13
Mediator of RNA polymerase II transcription subunit 13 (also known as THRAP1); a component of the mediator complex that can associate with numerous nuclear hormone receptors and have key roles in metabolic control. MED13 is regulated by the microRNA miR-208.
confers cardiac benefits in forms of heart disease beyond diastolic dysfunction remains to be determined.
Gene profiling studies have shown that the expression of a cohort of predicted mRNA targets is elevated in response to miR-208a inhibition in vivo, and many of these mRNA targets have unknown functions in the heart 48 . Although such genes serve as sensitive biomarkers of antimiR efficacy, their unknown functions underscore the challenges associated with establishing the mechanistic basis of the therapeutic efficacy of antimiR-208a.
Unexpectedly, mice treated with antimiR-208a display resistance to obesity, especially when on a high-fat diet 58 . This effect occurs in the absence of detectable toxicity and suggests that the heart has a role in systemic metabolic homeostasis and energy expenditure via a miR-208a-dependent mechanism. Among the strongest predicted and validated targets of miR-208a is mediator of RNA polymerase II transcription subunit 13 (MED13; also known as THRAP1), a component of the mediator complex, which interconnects RNA polymerase II at gene promoters with distal enhancers. Other mediator components have been shown to associate with numerous nuclear hormone receptors and to have key roles in metabolic control [59] [60] [61] . It is especially intriguing, in this regard, that cardiac-specific overexpression of MED13 confers resistance to obesity, as observed with miR-208a inhibition. Conversely, cardiacspecific deletion of MED13 results in obesity. These findings raise the possibility of developing antimiRs against miR-208a as therapeutic modifiers of metabolic syndrome (FIG. 3) . In this regard, other miRNAs, including miR-103, miR-107, miR-33 and let-7, have been implicated in systemic metabolic control in mice 38, [62] [63] [64] . . According to this model, upregulation of miR-21 in response to stress would be predicted to inhibit SPRY1 expression, thereby promoting MAPK signalling, whereas inhibition of miR-21 would have the opposite effect 9 .
There is also mounting evidence for the involvement of miR-21 in fibrosis of other tissues [65] [66] [67] [68] as well as in cancer 69 . Systemic delivery of miR-21 inhibitors, for example, has shown efficacy in suppressing extracellular matrix production in settings of muscular dystrophy, renal fibrosis and pulmonary fibrosis, suggesting that miR-21 occupies a central node in pathways of pathological fibrosis. The suppression of tumorigenesis by miR-21 inhibitors 69 appears to result from the regulation of different mRNA targets and exemplifies the ability of individual miRNAs to modulate distinct cellular processes depending on the physiological status of the cell and the abundance and availability of targets.
In contrast to these findings, mice with genetic deletion of miR-21 show no diminution in fibrosis in response to multiple cardiac stresses, indicating that miR-21 does not have an obligatory role in this pathological process 41 . Additionally, different antimiR chemistries show different functional outcomes with respect to miR-21 inhibition 41, 70 . For example, a 22-mer antimiR-21 modified by cholesterol, 2ʹ-F or 2ʹ-MOE prevented cardiac fibrosis and loss of cardiac contractility in mice subjected to thoracic aortic banding (TAB), whereas an 8-mer tiny LNA-modified antimiR-21 oligonucleotide showed no efficacy in suppressing fibrosis or preventing cardiac dysfunction following TAB in mice, despite forming a stable heteroduplex with the miR-21 target miRNA and inducing downstream target de-repression 41, 70 . The basis for the seemingly contradictory conclusions regarding the role of miR-21 in fibrosis has not been resolved, but there are several potential explanations. It is conceivable, for example, that genetic deletion of miR-21 throughout embryonic and postnatal stages allows for compensatory mechanisms that substitute for miR-21 function, and such mechanisms are not deployed under conditions of acute miR-21 inhibition with antagomirs. Alternatively, or in addition, individual antimiR-21 chemistries might have a different mode of action, hence resulting in a different outcome.
Studies by Care et al. 71 and Liu et al. 72 further document the discrepancies in phenotypic outcomes resulting from oligonucleotide-based miRNA inhibition versus genetic deletion of a miRNA. In this case, antagomirmediated inhibition of miR-133 induced cardiac hypertrophy in mice 71 , whereas genetic deletion of miR-133 resulted in partial lethality and a dilated cardiomyopathy in the survivors 72 .
Control of cardiomyocyte apoptosis and regeneration by the miR-15 family. Members of the miR-15 family, which includes miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195 and miR-497, have been implicated in cell cycle arrest and cell survival in several cell types, by regulating many anti-apoptotic and cell cycle genes 73 . Members of this miRNA family are upregulated in the heart in response to cardiac stress and myocardial infarction, which cause death of cardiomyocytes and loss of pump function 10 . Moreover, forced overexpression of miR-195 in the heart is sufficient to cause myocyte loss and heart failure, indicating that this miRNA family is a crucial component of heart disease pathogenesis 1 . The multiplicity of miR-15 family members exemplifies one of the challenges associated with miRNA inhibition as a therapeutic strategy, as sequence divergence among different members of miRNA families prevents their collective inhibition by the delivery of a single antisense oligonucleotide inhibitor.
One approach to potentially overcome such miRNA redundancy is the use of tiny 8-mer LNA-modified inhibitors, which target the conserved seed regions of miRNAs and thereby enable inhibition of co-expressed miRNA family members that may have redundant biological functions (FIG. 2) . A recent report showed that an 8-mer directed against the seed region of the miR-15 family was able to target mutiple members of the miR-15 family, which all contain a similar seed region but different 3ʹ regions 13 . In comparison with an LNA-modified 16-mer preferentially targeting miR-15b, the 8-mer was more efficacious in eliciting downstream target de-repression, whereas both chemistries were equally distributed to cardiac tissue in mice and pigs. Mouse efficacy studies, using a model of ischaemia reperfusion, showed that inhibition of the miR-15 family reduced infarct size and improved cardiac function 2 weeks after ischaemic damage 13 . Interestingly, miR-15 family members are also upregulated in the heart during the first few days after birth 74 . Recent studies have shown that the neonatal mouse heart is capable of complete regeneration following amputation of the apex or ischaemic injury during the period before miR-15 family upregulation 75 , and precocious upregulation of miR-195 in the heart suppresses this neonatal regenerative response. The inhibitory influence of miR-195 on heart muscle regeneration appears to be attributable to the inhibition of a cohort of proproliferative proteins 74 . Thus, antimiR-mediated inhibition of miR-15 family members represents an intriguing strategy to enhance cardiac repair following injury.
Control of stress-induced neoangiogenesis by miR-92a.
AntimiR strategies have also been effective in targeting miRNAs that are preferentially expressed in endothelial Nature Reviews | Drug Discovery
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Aneurysm
An abnormal widening or ballooning of a portion of an artery resulting from weakness in the wall of the blood vessel.
Marfan syndrome
A systemic connective tissue disorder in which aortic aneurysm formation is the leading cause of death.
and smooth muscle cells. miR-92a, a member of the miR-17-miR-92 cluster, has been implicated in neoangiogenesis following ischaemic injury 6 . Intravenous administration of a miR-92a antagomir showed efficacious inhibition of the miRNA, and resulted in enhanced blood vessel growth as well as functional improvement of damaged tissue in models of hindlimb ischaemia and myocardial infarction 6 . The neoangiogenic effect of inhibiting miR-92a in vivo was attributed to the derepression of several pro-angiogenic factors, including integrin α5 -a direct target of miR-92a. Although the pro-angiogenic effect of miR-92a inhibition is currently being explored as a potential therapeutic approach in diseases such as ischaemic heart disease or peripheral artery disease, additional studies have shown that miR-92a regulates the atheroprotective transcription factors Krüppel-like factor 2 (KLF2) and KLF4 (REFS 76, 77) . KLF2 and KLF4 regulate gene networks that confer atheroprotective properties to the endothelium through an antiinflammatory and anticoagulant effect 78 and, as such, antimiR-92a might exert comparable properties.
Control of extracellular matrix deposition by the miR-29 family.
A fibroblast-enriched miRNA family, miR-29, has shown strong coordinate effects by directly regulating the expression of at least 16 confirmed extracellular matrix genes 79 . The miR-29 family consists of miR-29a, miR-29b and miR-29c, which are expressed as two bicistronic clusters (miR-29a-miR-29b1 and miR-29b2-miR-29c) and are largely homologous in sequence, with several mismatches between the different members in the 3ʹ regions of the mature miRNA 10 . Members of the miR-29 family are downregulated in response to myocardial infarction in mice, specifically in the infarcted region, and their downregulation correlates with increased expression of extracellular matrix-related genes required for infarct healing 10 . Members of this miRNA family are also downregulated during pathological cardiac remodelling 1 . A cholesterol-conjugated miR-29 antagomir was detected in several tissues after delivery by i.v. injection in mice, which resulted in de-repression of several direct target genes 10 . The presence in the genome of four different copies of this miRNA with a comparable set of predicted targets, in combination with the fact that many of these verified targets are involved in extracellular matrix deposition, strongly supports a potent influence of miR-29 on fibrosis (FIG. 4) . miR-29 mimicry or overexpression could have therapeutic benefit in different forms of tissue fibrosis by inducing a subsequent decrease in the expression of fibrosis-related genes, as has been shown for heart 10 , kidney [80] [81] [82] , liver [83] [84] [85] , lung 86 and systemic sclerosis 87 . The obvious importance of this miRNA family was further demonstrated by recent reports on miR-29 inhibition for vascular indications. Levels of miR-29 were found to be upregulated in two animal models of aortic dilation as well as in biopsy samples of human thoracic aneurysms, which correlated with a profound downregulation of numerous extracellular matrix components 7, 88 . LNA-modified oligonucleotides against miR-29 were able to abrogate aortic dilation induced by angiotensin II in mice, which suggests that miR-29 inhibition could have a role in maintaining vascular integrity during aneurysm formation 7 . These data were confirmed by studies in two additional models of aortic aneurysms, showing that antimiR-29 induced an increase in collagen expression, resulting in a significant reduction in abdominal aneurysm progression 88 . The concept of miR-29 inhibition leading to enhanced vascular integrity was further supported by data showing that miR-29 has a role in early aneurysm formation in a mouse model of Marfan syndrome 89 . Finally, inhibition of miR-29 can dramatically increase elastin expression in cells from patients with elastin haploinsufficiencies, such as Williams-Beuren syndrome, which is characterized by aortic stenosis 90 . Combined, these data support miR-29 inhibition as a therapeutic approach in various vascular indications such as aneurysm formation; however, even though shortterm treatment with antimiR-29 does not appear to result in liver or kidney fibrosis 7 , adverse effects of stimulating extracellular matrix deposition should be considered in more chronic treatment regimens.
Control of viral myocarditis by miR-155. miR-155 is processed from an exon of a non-coding RNA transcribed from the B cell integration cluster (BIC), which is highly expressed in activated B and T cells as well as in monocytes Angiotensin II type 1 receptor (AT1). The receptor through which angiotensin II exerts most of its cardiac actions. This receptor has been associated with hypertension, cardiac hypertrophy and myocardial infarction, and is a direct target of the microRNA miR-155.
Viral myocarditis
Inflammation of the heart that can lead to cardiomyopathy. and macrophages 91 . miR-155 levels change dynamically during both haematopoietic lineage differentiation and the course of the immune response, and to date miR-155 has been implicated in several diseases, including cancer, cardiovascular disease and viral infections 92, 93 . With regard to cardiovascular disease, it was discovered that a single nucleotide polymorphism (+1166A/C) in the human angiotensin II type 1 receptor (AT1), the receptor through which angiotensin II exerts most of its actions, is associated with hypertension, cardiac hypertrophy and myocardial infarction, and disrupts a miR-155 binding site so it can no longer reduce AT1 expression 94 . Additional data suggesting that miR-155 might be involved in regulating blood pressure came from a study on homozygous twins discordant for trisomy 21. The participants of this study expressed elevated levels of miR-155 (located on chromosome 21), which correlated with a lower level of AT1 expression and low blood pressure 95 . Although it has been well established that miR-155 regulates myeloid and lymphoid immune cell function 96 , it has recently been shown that miR-155 is also upregulated during the acute inflammatory phase of viral myocarditis 97 . Acute viral myocarditis is an important cause of heart failure, resulting from infection of the heart by cardiotrophic viruses. In situ hybridization of heart tissue suffering from acute viral myocarditis indicates that the increase in miR-155 expression is induced by haematopoietic cells and all leukocyte subtypes, including macrophages and T cells. Therapeutic treatment with an antimiR against miR-155 elicited an increase in levels of miR-155 targets, and detection of 6-carboxyfluorescein (FAM)-labelled antimiR indicated a distribution of miR-155 to cardiomyocytes, endothelial borders as well as circulating monocytes, lymphocytes and neutro phils. Moreover, antimiR-155 treatment resulted in reduced myocardial damage and increased survival in response to viral myocarditis. This effect is likely to be immune-cell-autonomous as miR-155 inhibition did not affect viral load, myocyte viability or cytokine signalling in unstressed hearts before their infiltration by immune cells 97 . Although the authors did not observe an effect of antimiR treatment on cardiac fibrosis through a potential de-repression of AT1, this will have to be taken into account when considering antimiR-155 as a therapy for viral myocarditis.
Control of angiogenesis and vascular stability by miR-23, miR-27 and miR-24. Another miRNA cluster with prominent roles in vascular indications is the cluster composed of miR-23, miR-27 and miR-24. The human genome contains two versions of this cluster, both of which are enriched in endothelial cells 98, 99 . Members of this cluster are involved in cell cycle control as well as proliferation and differentiation of various cell types, and have important functions during angiogenesis 98, 99 . Choroidal neovascularization, which is characterized by abnormal vascular growth in the back of the eye, is a hallmark of age-related macular degeneration. A recent study by Zhou et al. 99 showed that miR-23 and miR-27 are upregulated during normal retinal vascular development and in response to laser-induced choroidal neovascularization. In vivo studies using LNA-modified antimiRs against both miR-23 and miR-27 demonstrated that inhibition of both miRNAs resulted in increased levels of SPRY2, semaphorin 6A and semaphorin 6D, which repressed neovascularization in the choroid in response to laser injury 99 . Interestingly, in vitro inhibition of either miR-23 or miR-27 in human umbilical vein endothelial cells caused a corresponding increase in miR-27 or miR-23 levels, respectively. In vivo inhibition of both miR-23 and miR-27 resulted in an increase in miR-24 levels. These effects are probably biological rather than chemical, as a scrambled oligonucleotide control with a comparable chemical composition did not induce this effect. Although this study did not present in vivo data after inhibition of either miR-23 or miR-27 alone, the in vitro data -based on target de-repression -seem to suggest that miR-27 is the major player. From a therapeutic standpoint, it would be a developmental challenge to investigate two compounds in parallel, and targeting two separate miRNAs could increase the risk of off-target effects.
The third member of the cluster, miR-24, was recently implicated in cardiac angiogenesis after myocardial infarction 100 . Cardiac ischaemia was shown to increase miR-24 levels in endothelial cells, and antagomir-based inhibition of miR-24 in endothelial cells reduced infarct size by preventing apoptosis and enhancing vascularity, probably through direct regulation of the transcription factors GATA2 and p21-activated kinase 4 (PAK4). Interestingly, in tracing the cellular fate of the antagomir by Cy labelling, the authors found that at a high dose (80 mg per kg) the antagomir was taken up by both cardio myocytes and endothelial cells, whereas at a lower dose (5 mg per kg) the antagomir was preferentially taken up by endothelial cells 100 . This might be relevant as it was previously shown that increased levels of miR-24 might have a cardioprotective effect in myocytes during an ischaemic event by decreasing the expression of the pro-apoptotic protein BIM (BCL-2 interacting mediator of cell death) 101 . These findings further highlight the potential functional differences of miRNAs in individual cell types, which should be taken into account when considering miR-24 as a therapeutic target.
Control of pulmonary hypertension by miR-145. Vascular smooth muscle cell (VSMC)-enriched miR-145 is expressed as part of the miR-143-miR-145 cluster 102 . Genetic deletion of this cluster showed that these miRNAs are essential for VSMC contractility 12, 102, 103 . Although miR-143 and miR-145 have distinct sequences, they coordinately regulate overlapping genes but also target different genes with regulatory functions in actin remodelling. Individual deletion of the miRNAs in mice indicated a prominent and distinct role for miR-145 in VSMC contractility, as this miRNA appeared to be mainly responsible for the thinning of the VSMC layer. Blood pressure analysis in these genetic models showed that removal of the cluster induced arterial hypotension at the baseline and reduced the increase in systolic pressure in response to angiotensin II 12, 102 . In lung samples of patients with both idiopathic and heritable pulmonary hypertension, miR-145 levels are upregulated in comparison with unaffected controls. Using chronic hypoxia as a model for pulmonary arterial hypertension in mice showed that antimiR-mediated inhibition of miR-145 reduced systolic right ventricular pressure 8 . Histological analysis supported these findings by showing that antimiR-145 reduced pulmonary vascular remodelling in response to hypoxia 8 . Although these initial data are encouraging and suggest that miR-145 inhibition has therapeutic potential in the setting of pulmonary arterial hypertension, genetic deletion of miR-145 resulted in a more pronounced phenotype as it reduced both blood pressure and right ventricular remodelling, which might indicate that the timing and incidence of dosing requires optimization. Additionally, as genetic deletion of the miRNA cluster indicates a more supportive function of this cluster in maintaining a normal VSMC phenotype and regulating normal contractility of arteries 12 , caution should be taken when applying antimiR strategies to more chronic diseases, and local delivery options should be contemplated.
Challenges in clinical development
The preclinical studies discussed above indicate that all cardiovascular cell types can be targeted by miRNA inhibitors, and inhibition of miRNAs can have profound effects on cardiovascular function, supporting enthusiasm for further exploration of miRNAs as novel drug candidates. However, numerous challenges and questions remain in the path towards the development of miRNA-based therapeutics in general. In most of the animal studies to date, the phenotypic effects of miRNA inhibition have only been studied in the target tissue of interest, which might overlook off-target effects in additional tissues. Moreover, the doses used in most studies are unlikely to be therapeutically feasible. Follow-up preclinical studies will have to guide appropriate dosing regimens in order to establish the lowest possible efficacious doses while attempting to prevent unacceptable side effects.
The identification and validation of miRNA targets is especially relevant to the development of miRNAbased therapeutics in general. In contrast to many other therapeutic modalities, antimiR drugs are designed with the understanding that they will affect all genes that are under the control of the target miRNA. Although miRNAs often target many related genes involved in cellular processes, which are intended to be manipulated by the antimiR therapeutic (FIG. 4) , a single miRNA will probably also target unrelated genes and possibly produce unexpected (and sometimes undesired) changes in gene expression. An excellent example of the diverse, and potentially unanticipated, actions of miRNAs was provided by the finding that antimiR therapeutics directed against the cardiac-specific miR-208a prevented obesity and metabolic syndrome in mice maintained on a highfat diet 58 . Before these findings, miR-208a was thought to function primarily to modulate myosin switching in striated muscle cells [55] [56] [57] . However, mechanistic follow-up of the metabolic effects of miR-208a inhibitors revealed a fascinating function of this miRNA in the regulation of a network of transcription factors that are involved in metabolic control and energy homeostasis. The potential pleiotropy of miRNA actions contrasts with the mechanistic basis of most classical drugs, which act with maximal specificity against single cellular targets. Additional ambiguity derives from the relatively modest inhibitory effects of individual miRNAs on mRNA targets, as revealed in miRNA loss-of-function studies. It is not uncommon, for example, for miRNA inhibition to result in minimal increases (<1.5-fold) in the expression of mRNA targets, suggesting that it is the cumulative impact of small changes in the expression of myriad targets -rather than pronounced changes in single targets -that mediates the biological actions of miRNAs on disease processes. Thus, it is often difficult or impossible to ascribe the effects of a miRNA to the regulation of a specific mRNA target. The multiplicity of miRNA targets also raises crucial issues with respect to possible off-target effects of miRNA inhibitors in different tissues and opposing actions of miRNAs on different phenotypic readouts. For example, if a miRNA displays broad tissue distribution, its systemic inhibition may have multiple effects in different tissues, thus confounding the interpretation of the responses to miRNA-based therapeutics. In addition, a miRNA may exert counterbalancing actions on cellular pathways such that the inhibition of a miRNA could, in principle, have both beneficial and deleterious consequences in the same or different tissues. Because miRNAs often control multiple components of complex regulatory networks, modulation of a specific miRNA -either up-or downregulation -can result in re-balancing of the network. In this respect, the multiplicity of miRNA targets can minimize bypass or desensitization mechanisms that can diminish the efficacy of certain drugs directed against single targets.
Despite these potential challenges, antimiR therapeutics have recently become a reality, following the successful Phase I and Phase II clinical trials of Santaris Pharma's antimiR against miR-122, miravirsen, which is currently in development for the treatment of HCV
. It is hoped that these promising findings will accelerate the development of miRNA-targeting therapeutics into additional disease areas such as cardiovascular disease.
miRNAs have also been found in plasma and blood samples and have emerged as potential biomarkers for disease. However, many questions remain regarding the basis for the altered expression of such biomarkers, their relationship to disease progression and their power for predicting disease progression and clinical outcome.
In conclusion, the obvious relevance and importance of miRNAs during disease, in addition to the success of the first clinical data showing the safety and efficacy of an antimiR, support enthusiasm for the continued exploration of miRNAs as a new class of drug targets.
